Octreotide

Octreotide
Product Description

Octreotide is the acetate salt of a cyclic octapeptide. It is a long-acting octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. Prevention and treatment of acute pancreatitis and upper gastrointestinal bleeding, and can also be used for portal hypertension and the treatment of ruptured esophageal gastric varices bleeding

Chengdu Shengnuo Biopharm Co Ltd

  • CN
  • 2015
    On CPhI since
Specifications
  • CAS Registry Number
    83150-76-9
  • Selling Points
    International Approvals/Standards
  • Supplied from
    China

Chengdu Shengnuo Biopharm Co Ltd

  • CN
  • 2015
    On CPhI since

More Products from Chengdu Shengnuo Biopharm Co Ltd

  • Bivalirudin

    Product Bivalirudin

     Use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty .Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important to monitor changes in hematocrit, activated partial thromboplastin time, international normalized ratio and blood pressure.
  • Liraglutide

    Product Liraglutide

    Diabetes mellitus, 
    Liraglutide is a once-daily GLP-1 derivative for the treatment of type 2 diabetesLabel,2. The prolonged action of liraglutide is achieved by attaching a fatty acid molecule at position 26 of the GLP-1 molecule, enabling it to bind reversibly to albumin within the subcutaneous tissue and bloodstream and be released slowly over timeLabel,2,3. Binding with albumin results in slower degradation and reduced elimination of liraglutide from the circulation by the kidneys compared to GLP-12,3. The effect of liraglutide is the increased secretion of insulin and decreased secretion of glucagon in response to glucose as well as slower gastric emptyingLabel. Liraglutide also does not adversely affect glucagon secretion in response to low blood sugar
  • Icatibant

    Product Icatibant

    is a synthetic peptidomimetic drug consisting of ten amino acids, and acts as an effective and specific antagonist of bradykinin B2 receptors. It has been approved in the EU for use in hereditary angioedema, and is under investigation for a number of other conditions in which bradykinin is thought to play a significant role. Icatibant currently has orphan drug status in the United States and FDA approved on August 25, 2011.  HAE (hereditary angiodysplasia)

Recommended products